Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher

Core Viewpoint - Indivior (INDV) has shown significant stock performance, rising nearly 200% in the past year, with a notable increase in profitability and revenue projections for 2025 and beyond [2][4]. Financial Performance - In the first half of fiscal 2025, Indivior generated a GAAP profit of $65 million, a 281% increase compared to a $36 million loss in the same period the previous year [4]. - The company expects full-year revenue of $1.055 billion and adjusted EBITDA of $287.5 million at the midpoint of its guidance for 2025 [5]. - Following the release of Q3 2025 results, the company raised its revenue guidance to $1.2 billion, an increase of $145 million from previous estimates, and adjusted EBITDA to $410 million, up $122.5 million [6]. Product Performance - Sublocade, a once-monthly injection for opioid addiction, accounted for 68% of Indivior's $568 million in net revenue for the first half of fiscal 2025 [5]. - The company is focused on maintaining momentum by adding new treatments to its lineup, which is expected to further enhance profitability [2][3].